Up to a year of treatment with Firdapse (amifampridine) was well tolerated, improved muscle strength, and eased symptoms in…
Articles by Steve Bryson, PhD
The U.S. Food and Drug Administration (FDA) has agreed to review Catalyst Pharmaceuticals’ request to raise to 100…
People with one or more rare diseases, such as Lambert-Eaton myasthenic syndrome (LEMS), face a wide range of obstacles…
The National Organization for Rare Disorders (NORD) is hosting community listening sessions for Latino and Spanish-speaking people in the…
People with small cell lung cancer (SCLC) treated with the immune-based cancer therapy atezolizumab are at an increased risk of…
Lambert-Eaton myasthenic syndrome (LEMS) arose in association with a rare type of aggressive skin cancer called Merkel cell carcinoma…
Muscle responses to low-frequency repetitive nerve stimulation in people with Lambert-Eaton myasthenic syndrome (LEMS) were different from those of…
Plasma exchange therapy eased the symptoms of a man with Lambert-Eaton myasthenic syndrome (LEMS) who tested negative for…
A rare case of Lambert-Eaton myasthenic syndrome (LEMS) triggered by an immune-related cancer therapy was recently described in a…
Catalyst Pharmaceuticals has announced its partner DyDo Pharma has launched a Phase 3 registrational trial in Japan to…